Team targets tumor suppressor to treat ‘triple-negative’ breast cancer

0
1965

A study by scientists at the University of Arizona Cancer Center and Cancer Research UK has found that the loss of a specific tumor suppressor in “triple-negative” breast cancer provides clues about potential new approaches to treatment.

The results were published on Jan. 30 in the journal Cell Reports.

Triple-negative breast cancers lack three receptors that can be targeted by drugs, which limits treatment options.

Therapy can be “targeted” to be more specific to a patient’s individual tumor profile, allowing for the delivery of “personalized” medicine.

Currently, patients with triple-negative breast cancer are treated with radiation or chemotherapy, and lack options for targeted forms of treatment.

In response, the UA Cancer Center’s Agnieszka Witkiewicz, MD, professor of pathology, and Erik Knudsen, PhD, professor of medicine at the UA College of Medicine – Tucson, analyzed unique features of triple-negative breast cancer to identify possible new approaches for treatment.

Previous research from the group showed that about 20 to 30 percent of triple-negative breast cancers have lost the retinoblastoma (RB) tumor suppressor. Drs. Witkiewicz and Knudsen hypothesized that loss of this tumor suppressor in the subset of triple-negative breast cancers may provide a target for novel drugs.

A properly functioning RB tumor suppressor is present in normal breast cells and helps to maintain control over cell division.

The loss of the RB tumor suppressor impairs one of the body’s critical defense mechanisms against cancer formation.

“The lack of a personalized strategy to apply medicine based on specific features of a patient’s tumor remains one of the seminal therapeutic challenges in the treatment of triple-negative breast cancer,” said Dr. Witkiewicz.

“Therefore, exploiting the loss of RB could represent a significant conceptual change in the way we consider treatment.”

Three promising candidates emerged from a search for drugs that could target triple-negative breast cancers with the missing RB tumor suppressor.

These tumors were susceptible to drugs that target PLK1 and AURK, proteins that are key drivers of cell division, and CHK1, a protein that is important for DNA replication.

These proteins can be used as biomarkers, properties of a tumor that can be measured in blood to let doctors know more about a patient’s cancer and how best to treat it.

The studies showed that triple-negative breast tumors lacking the RB tumor suppressor harbor increased levels of these biomarkers.

Developing drugs that target PLK1, AURK and CHK1 could represent a strategy for treating the 20 to 30 percent of triple-negative breast cancer patients whose tumors do not respond to targeted treatments.

“Drugs that attack PLK1 or CHK1 wreak catastrophic damage on tumor cells that have lost RB,” said Dr. Knudsen.

“These studies underscore the importance of understanding fundamental features of tumor cell division and delineating how to target tumor-specific vulnerabilities with new drugs to exploit those events therapeutically.”

The authors caution that these findings, while provocative, need further exploration.

The group is planning studies to investigate PLK1, AURK and CHK1 inhibitors in clinical trials to test the effectiveness of drugs that target RB-deficient triple-negative breast cancer.

“A biomarker-driven clinical trial will be critical in advancing this concept from the laboratory to the clinic,” said Dr. Witkiewicz.

Breast cancer is the most common type of cancer in the United States, with an estimated 252,710 diagnoses and 40,610 deaths in 2017, according to the National Cancer Institute.

About 10 to 20 percent of breast cancers are triple-negative, and targeted treatments are necessary to decrease mortality associated with this aggressive form of the disease. Beyond triple-negative breast cancer, drugs that target RB-deficient tumors could have implications for other types of cancers in which tumors lose the RB tumor suppressor.

Journal reference: Cell Reports search and more info website

Provided by: University of Arizona Health Sciences

 

What is triple-negative breast cancer?

About 15 to 20 percent of breast cancers are triple-negative, but you may never have heard of triple-negative breast cancer before you received your test results.

Hearing new words and not understanding what they mean may make you feel scared and overwhelmed.

Knowing breast cancer basics can help you understand how triple-negative breast cancer is different from other types of breast cancer.

To find out what type of breast cancer you have, your doctors search for the presence or absence of receptors, proteins that live inside or on the surface of a cell and bind to something in the body to cause the cell to react.

You may have heard of the  estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2).

In estrogen receptor-positive breast cancer, progesterone receptor-positive breast cancer and HER2-positive breast cancer, treatment includes medicines that prevent, slow or stop cancer growth by targeting those receptors.

But triple-negative breast cancers (TNBC) need different types of treatments because they are estrogen receptor-negative, progesterone receptornegative and HER2-negative.

Medicines like tamoxifen, which targets the estrogen receptor, and rastuzumab (Herceptin), which targets HER2, are not helpful in treating triple-negative breast cancer.

Instead, chemotherapy has been shown to be the most effective treatment for triple-negative breast cancer.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.